key: cord-0686767-3yh8d2cn
authors: Manjunath, Souparnika H.; Thimmulappa, Rajesh K.
title: Antiviral, immunomodulatory, and anticoagulant effects of quercetin and its derivatives: Potential role in prevention and management of COVID-19
date: 2021-09-20
journal: J Pharm Anal
DOI: 10.1016/j.jpha.2021.09.009
sha: 092dc5b8239f674b31b229e5dbadf02941b880cf
doc_id: 686767
cord_uid: 3yh8d2cn

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a devastating health crisis worldwide. In this review, we have discussed that prophylactic phytochemical quercetin supplementation in the form of foods or nutraceuticals may help manage the COVID-19 pandemic. The following evidence supports our argument: first, nuclear factor erythroid-derived 2-like 2 (NRF2) agonists abrogated replication of SARS-CoV-2 in lung cells, and quercetin is a potent NRF2 agonist; second, quercetin exerts antiviral activity against several zoonotic coronaviruses, including SARS-CoV-2, mainly by inhibiting the entry of virions into host cells; third, inflammatory pathways activated by nuclear factor kappa B (NF-κB), inflammasome, and interleukin-6 (IL-6) signals elicit cytokine release syndrome that promotes acute respiratory distress syndrome in patients with COVID-19, and quercetin inhibits these pro-inflammatory signals; fourth, patients with COVID-19 develop thrombosis, and quercetin mitigates coagulation abnormalities by inhibiting plasma protein disulfide isomerase. This review provides a strong rationale for testing quercetin for the management of COVID-19.

Coronavirus disease-2019 (COVID-19) caused by severe active respiratory syndrome 30 (SARS) coronavirus 2 (SARS-CoV-2) infection has caused an unprecedented global health crisis 31 and economic loss. As of August 7, 2021, over 201 million people were infected with SARS-32

CoV-2, and 4.2 million people died worldwide [1] .The common symptoms recorded among 33 patients with non-severe COVID-19 include fever, fatigue, dry cough, sputum production, 34

headache, and dyspnea associated with mild unilateral or bilateral pneumonia. Meanwhile, 35

patients with severe COVID-19 disease are associated with pneumonia, acute respiratory distress 36 syndrome (ARDS), metabolic acidosis, thromboembolism, multiple organ failure, and acute 37 cardiac injury [2,3], which are common factors contributing to death. Although SARS-CoV-2 38 has affected every age group, from newborn to children to adults, severe morbidity and mortality 39 are commonly observed in the elderly population aged > 60 years and people with comorbidities, 40 such as hypertension, diabetes, cardiovascular disease, and renal disease. 41

Currently, the treatment modalities for hospitalized patients with COVID-19 involve 42 supportive care, such as supplemental oxygen therapy and mechanical ventilation, and there are 43 no Food and Drug Administration (FDA)-approved drugs for COVID-19 treatment. Nonetheless, 44

few FDA-approved drugs are being repurposed for COVID-19 management; however, the 45 outcomes have been mixed. During the early phase of the pandemic, the antimalarial drug 46 hydroxychloroquine and anti-human immunodeficiency virus (HIV) drug lopinavir/ritonavir 47 were repurposed for the treatment of COVID-19; however, the trials were discontinued by the 48

World Health Organization (WHO) as there were no significant clinical benefits between the 49 repurposed drug and standard of care. Remdesivir, a small molecule inhibitor of viral RNA-50 dependent RNA polymerase used initially against the Ebola virus, has been administered at the 51 bedside for the management of patients with COVID-19, and the results were promising. 52

Remdesivir did not lower the mortality of hospitalized patients with COVID-19; however, it 53 shortened the recovery time of severely ill patients compared to patients who were receiving 54 standard care of treatment [4]. A more recent success story was from the clinical trials of 55 dexamethasone, a glucocorticoid drug, which dampens host inflammatory responses. 56

Dexamethasone treatment significantly lowered 28 day mortality among mechanically ventilated 57 patients with COVID-19 compared to placebo [5] . Based on the knowledge gained from a 58 mechanistic understanding of COVID-19 pathogenesis and big-data analysis using artificial 59 intelligence, several approved drugs are being repositioned for COVID-19 treatment [6] . to identify potential antiviral phytochemical(s) against SARS-CoV-2 [10] . Quercetin, a flavonoid 81 present in many fruits and vegetables, has been identified as a promising candidate that exhibits a 82 broad-spectrum antiviral activity. In silico data suggest that quercetin interacts with SARS-CoV-83 2 spike protein and main proteases, and it may be useful in inactivating or killing SARS-CoV-2 84 [11, 12] . In this review, we have integrated the latest and established evidences on quercetin and 85 postulated that it confers prophylactic and therapeutic benefits in the management of COVID-19. 86 We have built a strong case for the plausible use of quercetin or its derivatives as 87 chemoprotective nutraceutical agents for the protection of the general public from SARS-CoV-2 88 infection and management of patients with COVID-19. 89

Quercetin is a pentahydroxyflavone with hydroxy groups at the 3-, 3′-, 4′-, 4, and 7-91 positions (Fig. 1) , and it belongs to the flavonol subclass of flavonoids. Quercetin is an aglycone; 92 however, it is usually conjugated to simple sugars (i.e., glucose, xylose, rhamnose, arabinose, or 93 galactose) or disaccharide (e.g., rutinose) at the 3-position in plants (Fig. 1 quercetin supplementation may attenuate SARS-CoV-2 replication through the activation of 136 NRF2 (Fig. 2) . 137

The 3C-like proteases (3CL pro ; also referred as the main protease) and papain-like protease 139

(PL pro ) are highly conserved among human coronaviruses and are attractive drug targets. 140

Following coronavirus infection, 3CL pro and PL pro are translated and activated, which then cleave 141 J o u r n a l P r e -p r o o f the polyproteins pp1a and pp1ab into various non-structural proteins, including RNA-dependent 142 RNA polymerase, which is essential for viral replication. suggests that quercetin or its analogs inhibit 3CL pro activity, which is vital in the replication of 150 coronaviruses, including SARS-CoV-2.  Quercetin may inhibit SARS-CoV-2 entry into cells by altering viral envelope proteins  Quercetin may inhibit SARS-CoV-2 replication by activating the NRF2 pathway  Quercetin attenuates proinflammatory signals and cytokine release syndrome  Quercetin may reduce coagulopathy by inhibiting protein disulphide isomerase

Dexamethasone in Hospitalized Patients with

Artificial intelligence in COVID-19 drug repurposing

Efficacy and Safety of COVID-19 Vaccines in Phase III 318 Trials: A Meta-Analysis, Vaccines

Clinical features and treatment of COVID-19 patients in 320 northeast Chongqing

Analysis on herbal medicines utilized for treatment of 322 COVID-19

Natural product-derived phytochemicals as 324 potential agents against coronaviruses: A review

Can phytotherapy with polyphenols serve as a 326 powerful approach for the prevention and therapy tool of novel coronavirus disease 2019 327 (COVID-19)?

In silico pharmacokinetic and molecular 329 docking studies of natural flavonoids and synthetic indole chalcones against essential 330 proteins of SARS-CoV-2

Variation of quercetin glycoside derivatives in 332 three onion (Allium cepa L.) varieties, Saudi

The Molecular Mechanisms Regulating the KEAP1-NRF2

SARS-CoV2-mediated suppression of NRF2-338 signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and 339 dimethyl fumarate

Quercetin induces the expression of 341 peroxiredoxins 3 and 5 via the Nrf2/NRF1 transcription pathway

Action of Nrf2 and Keap1 in ARE-mediated NQO1 344 expression by quercetin, Free Radic

The dietary antioxidant quercetin reduces 346 hallmarks of bleomycin-induced lung fibrogenesis in mice

Dihydroquercetin protects against renal fibrosis by 349 activating the Nrf2 pathway

Characteristics of flavonoids as potent MERS-CoV 3C-like 351 protease inhibitors

Flavonoid-mediated inhibition of SARS 353 coronavirus 3C-like protease expressed in Pichia pastoris

Structural stability

CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening

Biflavonoids from Torreya nucifera displaying 359 SARS-CoV 3CL(pro) inhibition

Small molecules blocking the entry of severe acute respiratory 361 syndrome coronavirus into host cells

A pneumonia outbreak associated with a new 363 coronavirus of probable bat origin

Evaluation of flavonoids as 2019-nCoV cell 365 entry inhibitor through molecular docking and pharmacological analysis

Quercetin as an Antiviral Agent Inhibits Influenza A Virus 368 (IAV) Entry

Probing the effect of quercetin 3-glucoside from 370

Dianthus superbus L against influenza virus infection-In vitro and in silico biochemical 371 and toxicological screening

Inhibitory effects of quercetin 3-rhamnoside on 373 influenza A virus replication

Quercetin 3-rhamnoside exerts antiinfluenza A virus activity 375 in mice

Quercetin pentaacetate inhibits in 377 vitro human respiratory syncytial virus adhesion

Biophysical and flavonoid-379 binding studies of the G protein ectodomain of group A human respiratory syncytial virus

Anti-human rhinovirus 2 activity and mode of 382 action of quercetin-7-glucoside from Lagerstroemia speciosa

Quercetin inhibits rhinovirus replication in 385 vitro and in vivo

Quercetin prevents rhinovirus-induced 387 progression of lung disease in mice with COPD phenotype

Clinical and immunological assessment of 390 asymptomatic SARS-CoV-2 infections

Longitudinal analyses reveal immunological misfiring 392 in severe COVID-19

IL-6 trans-signaling induces plasminogen activator 394 inhibitor-1 from vascular endothelial cells in cytokine release syndrome

Genetic variants mimicking therapeutic inhibition 397 of IL-6 receptor signaling and risk of COVID-19

Cytokine release syndrome in severe COVID-19

Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug 401 Target in the Treatment of COVID-19

Quercetin inhibits TNF-induced NF-kappaB 403 transcription factor recruitment to proinflammatory gene promoters in murine intestinal 404 epithelial cells

Quercetin inhibits expression of inflammatory 406 cytokines through attenuation of NF-kappaB and p38 MAPK in HMC-1 human mast cell 407 line

Induced Inflammatory Cytokines and Chemokines in ARPE-19 Cells via the MAPK and 410 NF-κB Signaling Pathways

Quercetin protects against lipopolysaccharide-induced acute 412 lung injury in rats through suppression of inflammation and oxidative stress

Computational screen and experimental validation of anti-415 influenza effects of quercetin and chlorogenic acid from traditional Chinese medicine

Quercetin suppresses NLRP3 inflammasome activation 418 and attenuates histopathology in a rat model of spinal cord injury

The inhibitory effect of quercetin on IL-6 production by LPS-421 stimulated neutrophils

Immunosuppressive effect of quercetin on 423 dendritic cell activation and function

Quercetin Interrupts the Positive 425 Feedback Loop Between STAT3 and IL-6, Promotes Autophagy, and Reduces ROS

/STAT3 signaling and inhibits glioblastoma cell line growth and migration

Resveratrol suppresses IL-6-induced ICAM-1 gene 431 expression in endothelial cells: effects on the inhibition of STAT3 phosphorylation

Nrf2 is a critical regulator of the innate 434 immune response and survival during experimental sepsis

Enhancing Nrf2 pathway by disruption of 437 Keap1 in myeloid leukocytes protects against sepsis

Nrf2 suppresses macrophage 440 inflammatory response by blocking proinflammatory cytokine transcription

Endotheliopathy in COVID-19-associated 443 coagulopathy: evidence from a single-centre, cross-sectional study

Coagulation abnormalities and thrombosis in patients 446 with COVID-19

Thrombosis in Hospitalized Patients 448 With COVID-19 in a New York City Health System

Abnormal coagulation parameters are associated with poor 450 prognosis in patients with novel coronavirus pneumonia

Coagulopathy of Coronavirus Disease

Targeting protein disulfide isomerase with 455 the flavonoid isoquercetin to improve hypercoagulability in advanced cancer

Protein disulfide isomerase inhibition blocks 458 thrombin generation in humans by interfering with platelet factor V activation

Potential Clinical Benefits of Quercetin in the 463

Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-464 Label Clinical Trial

A Phase I Dose Escalation Study Demonstrates 466

Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with 467 Chronic Hepatitis C

Quercetin reduces illness but not immune 469 perturbations after intensive exercise

Randomised clinical trial to determine the 471 safety of quercetin supplementation in patients with chronic obstructive pulmonary disease

Enzymatically modified isoquercitrin 474 improves endothelial function in volunteers at risk of cardiovascular disease